Attention Deficit Hyperactivity Disorder. Hyperkinetic disorders
Conditions
Interventions
Intervention 1: intervention group: The starting dosage of Aripiprazole is 1.25 mg daily and it will increase 1.25 mg per day every other week depends on the child response. At the same time, they wi
Placebo
Treatment - Drugs
intervention group: The starting dosage of Aripiprazole is 1.25 mg daily and it will increase 1.25 mg per day every other week depends on the child response. At the same time, they will receive place
Control group: The starting dosage of Risperidone is 0.25 mg daily and it will increase 0.25 mg per day every other week depends on the child response. At the same time, they will receive placebo of A
Sponsors
Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 6 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Children from age three to age six with Attention Deficit Hyperactivity Disorder Exclusion Criteria: co-morbidity with Bipolar Disorder; Psychotic Disorder; Mental Retardation;Autistic Disorder;Developmental Delay Disorder; Epilepsy; Any unstable physical conditions that preclude the use of oral medication or continuing treatment process;taking any psychotropic medication in two weeks prior to study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attention Deficit Hyperactivity scores. Timepoint: two weeks, four weeks, eight weeks and twelve weeks after intervention. Method of measurement: ADHD-RS, C-GAS, CRSP. | — |
Secondary
| Measure | Time frame |
|---|---|
| Medication side effects. Timepoint: Second week. Four weeks, eight weeks, twelve weeks after the intervention. Method of measurement: Side Effect Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Arash Danesh
Behavioral Sciences Research, Shahid Beheshti University of Medical Sciences
Outcome results
None listed